Table 1.
Baseline characteristics, lipids, and sterols
|
A. Overall and subgroups by statin potency
| ||||
|---|---|---|---|---|
| Characteristic | Overall | Statin potency | ||
| (n=874) | Low (N=133) |
Medium (N=582) |
High (N=159) |
|
| Mean age (yr) | 61.3 ±11.2 | 62.0 ±11.2 | 61.4 ±11.2 | 60.5 ±11.0 |
| Male (%) | 473 (54.1) | 68 (51.1) | 312 (53.6) | 93 (58.5) |
| Race | ||||
| Caucasian, n (%) | 722 (82.6) | 97 (72.9) | 485 (83.3) | 140 (88.1) |
| African American, n (%) | 67 (7.7) | 10 (7.5) | 45 (7.7) | 12 (7.5) |
| Others, n (%) | 85 (9.7) | 26 (19.5) | 52 (8.9) | 7 (4.4) |
| DM, n (%) | 361 (41.3) | 61 (45.9) | 253 (43.5) | 47 (29.6) |
| Body mass index (kg/m2) | 30.8 ±6.6 | 30.1 ±7.5 | 31.0 ±6.5 | 30.7 ±6.1 |
| Total C (mg/dl) * | 210.7 ±34.2 | 215.8 ±35.2 | 208.7 ±32.4 | 213.6 ±39.1 |
| LDL-C (mg/dl) ** | 129.5 ±29.0 | 135.1 ±30.1 | 127.0 ±26.4 | 134.1 ±35.2 |
| Triglyceride (mg/dl) a | 151.0 ±83.7 | 152.0 ±75.3 | 151.0 ±81.9 | 150.0 ±91.2 |
| HDL-C (mg/dl) | 48.1 ±11.3 | 47.9 ±11.9 | 48.6 ±11.3 | 46.5 ±10.5 |
| Total C/HDL-C ratio ** | 4.56 ±1.12 | 4.74 ±1.29 | 4.46 ±1.06 | 4.76 ±1.15 |
| Non-HDL-C (mg/dl) ** | 162.5 ±33.1 | 167.8 ±35.8 | 160.1 ±31.0 | 167.1 ±37.0 |
| Apo B (mg/dl) ** | 129.2 ±24.8 | 132.1 ±27.1 | 127.3 ±23.6 | 133.8 ±26.7 |
| Apo A1 (mg/dl) * | 158.1 ±26.9 | 157.8 ±27.2 | 159.7 ±27.1 | 152.4 ±25.2 |
| hs-CRP (mg/L) a | 2.50 ±3.72 | 2.80 ±3.91 | 2.50 ±3.53 | 2.40 ±4.37 |
| Lathosterol (μmol/L) *** | 2.55 ±1.70 | 3.17 ±1.70 | 2.58 ±1.70 | 1.93 ±1.63 |
| β-sitosterol (μmol/L) *** | 4.86 ±2.62 | 4.51 ±2.03 | 4.58 ±2.46 | 6.21 ±3.14 |
| Lathosterol/Total C (μmol/mmol) *** | 0.46 ±0.27 | 0.56 ±0.27 | 0.47 ±0.27 | 0.34 ±0.24 |
| β-sitosterol/Total C (μmol/mmol) *** | 0.91 ±0.50 | 0.83 ±0.39 | 0.86 ±0.47 | 1.15 ±0.60 |
| β-sitosterol/Lathosterol *** | 3.16 ±3.53 | 2.03 ±2.22 | 2.77 ±3.08 | 5.50 ±4.78 |
|
B. Subgroups by statin type
| ||||
|---|---|---|---|---|
| Characteristic | Atorvastatin | Simvastatin | Pravastatin | Other statinsa |
| (n=345) | (n=233) | (n=209) | (n=87) | |
| Mean age (yr) | 60.0±11.7 | 61.6±10.3 | 61.6±11.4 | 63.2±10.2 |
| Male (%) | 182 (52.8%) | 143 (61.4%) | 104 (49.8%) | 44 (50.6%) |
| Race | ||||
| Caucasian, n (%) | 286 (82.9) | 195 (83.7) | 167 (79.9) | 74 (85.1) |
| African American, n (%) | 29 (8.4) | 19 (8.2) | 14 (6.7) | 5 (5.7) |
| Other, n (%) | 30 (8.7) | 19 (8.2) | 28 (13.4) | 8 (9.2) |
| DM, n (%) | 136 (39.4) | 98 (42.1) | 88 (42.1) | 39 (44.8) |
| Body mass index (kg/m2) | 31.1 ±6.5 | 30.8 ±6.5 | 30.2 ±5.9 | 30.9 ±8.8 |
| Total C (mg/dl) ** | 209.7 ±35.4 | 205.5 ±31.4 | 215.5 ±34.9 | 216.4 ±33.2 |
| LDL-C (mg/dl) ** | 130.0 ±30.9 | 124.3 ±26.1 | 133.1 ±28.3 | 133.4 ±28.1 |
| Triglyceride (mg/dl) b | 149.0± 85.6 | 149.0 ±88.4 | 155.0 ±80.0 | 157.0 ±69.8 |
| HDL-C (mg/dl) | 47.8 ±10.7 | 48.2 ±11.8 | 48.6 ±12.0 | 48.4 ±10.3 |
| Total C/HDL-C ratio ** | 4.55 ±1.05 | 4.46 ± 1.10 | 4.65 ±1.25 | 4.64 ±1.09 |
| Non-HDL-C (mg/dl) ** | 162.0 ±33.6 | 157.4 ±30.2 | 166.9 ±34.5 | 168.0 ±33.1 |
| Apo B (mg/dl) * | 129.2 ±25.4 | 125.8 ±23.2 | 131.3 ±26.0 | 133.4 ±23.0 |
| Apo A1 (mg/dl) | 156.3 ±26.1 | 157.7 ±26.3 | 160.5 ±28.2 | 160.0 ±28.0 |
| hs-CRP (mg/l) b | 2.40 ±3.53 | 2.50 ± 3.81 | 2.70 ±4.09 | 2.50 ± 3.53 |
| Lathosterol (μmol/L) *** | 2.20 ±1.70 | 2.47 ±1.68 | 3.08 ±1.69 | 2.91 ±1.42 |
| β-sitosterol (μmol/L) *** | 5.40 ±2.93 | 4.33 ±2.17 | 4.72 ±2.51 | 4.48 ±2.25 |
| Lathosterol/Total C (μmol/mmol) *** | 0.39 ±0.26 | 0.46 ±0.28 | 0.55 ±0.26 | 0.52 ±0.24 |
| β-sitosterol/Total C (μmol/mmol) *** | 1.01 ±0.57 | 0.82 ±0.40 | 0.86 ±0.48 | 0.81 ±0.42 |
| β-sitosterol/Lathosterol *** | 4.22 ±4.39 | 2.86 ±2.96 | 2.11 ±2.10 | 2.23 ±2.62 |
a
Values are expressed as mean ± standard deviation (SD) or median ± robust SD
*
p <0.05;
**
p <0.01;
***
p <0.001 indicate significant differences between statin potency groups by ANOVA
Apo; apolipoprotein; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; Total C, total cholesterol
a
other statins include lovastatin and fluvastatin
b
Values are expressed as mean ± standard deviation (SD) or median ± robust SD
*
p <0.05;
**
p <0.01;
***
p <0.001 indicate significant differences between statin potency groups by ANOVA
Abbreviations as in Table 1A